Latest studies
- RecruitingPhase III
A Phase III trial of inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease
This clinical trial is testing an inhaled medicine called mosliciguat for people with high blood pressure in the lungs caused by lung scarring. Researchers want to see if breathing in this drug helps people walk further over six minutes compared to a dummy inhaler with no active medicine.
Pulmonary hypertension associated with interstitial lung diseaseAustria - CompletedPhase II
A trial of BEvACizumab added to temozolomide +/- irinOtecan for children with refractory/relapsed Neuroblastoma
This study looks at new treatment combinations for children and young people with neuroblastoma that has returned or stopped responding to standard therapy. Researchers want to see if adding an antibody drug called bevacizumab to chemotherapy can help control the cancer and improve treatment options.
Neuroblastoma in children aged ≥1 to ≤21 yearsAustria - CompletedNot Applicable
LOTUS: LOng-Term follow-Up Study of triple-negative breast cancer
The LOTUS study is looking at the long-term health of people with triple-negative breast cancer who previously took part in a trial called BEATRICE. Researchers want to understand how past treatments affect health over many years, helping doctors improve care and support for future patients.
Triple-negative breast cancerAustria - RecruitingPhase II
A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
This study is testing a new capsule called ZED1227 for adults with coeliac disease. Researchers want to see if this medicine can protect the gut and ease lingering tummy symptoms caused by accidental gluten exposure, even in people who already follow a strict gluten-free diet.
Coeliac diseaseAustria - RecruitingPhase I/II
A trial looking at different treatments for neuroblastoma which has come back after initial therapy
The BEACON2 trial is testing new combinations of cancer medicines for children and young people whose neuroblastoma has returned or worsened after initial treatment. The goal is to find out which drug combinations are safest and work best to control the disease and improve future care.
Relapsed NeuroblastomaAustria - RecruitingPHASE3
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
This study, called DLLEVATE, is looking at a new treatment, ZL-1310, for people with small cell lung cancer that has come back. It compares ZL-1310 to other standard treatments to see if it's safe and works well. You might be eligible if you're over 18 and have had previous treatments.
Small-cell Lung CancerAustria - RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaAustria - RecruitingPHASE3
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
This study looks at a new drug, elritercept, for people with myelofibrosis and anaemia who are already taking ruxolitinib. It compares elritercept to a dummy drug (placebo) to see if it improves anaemia and other symptoms, and how safe it is.
MyelofibrosisAnemiaAustria - Completed
Vitamin D and lifestyle Intervention for gestational diabetes mellitus (GDM) prevention
This study looks at ways to prevent gestational diabetes, which is high blood sugar during pregnancy. Researchers are testing whether vitamin D supplements, healthy eating advice, regular physical activity, or combinations of these can help pregnant women with a higher body mass index stay healthy throughout their pregnancy.
Gestational diabetesAustria - RecruitingPHASE3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
This study looks at a new treatment called AAA617 for men with early-stage prostate cancer that has spread a little (oligometastatic). It compares AAA617 to careful watching, to see if it can stop the cancer from growing and help men live better for longer.
Oligometastatic Prostate Cancer (OMPC)Austria - RecruitingPhase III
Phase 3, randomised, double-blind, placebo- controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with biopsy-confirmed F2- or F3-stage metabolic dysfunction-associated steatohepatitis (MASH) (ZENITH-1)
This clinical trial is testing a new injection called efimosfermin alfa for people with metabolic dysfunction-associated steatohepatitis (MASH), an inflamed fatty liver condition. Researchers want to see if monthly injections over four years can safely reduce liver fat, ease inflammation, and improve liver scarring compared to a dummy treatment.
Medical condition: Metabolic Dysfunction-Associated Steatohepatitis (MASH) Medical condition in lay language: Metabolic Fatty Liver Inflamation Therapeutic areas: Diseases [C] - Nutritional and Metabolic Diseases [C18]Austria - Completed
Evaluation of a dermocosmetic regimen for acne-prone skin in volunteers with mild, moderate or severe skin conditions
Acne is a common skin condition that affects confidence and well-being. This study tests whether a daily skincare routine using Eucerin products helps clear mild to severe spots. Researchers want to see how well these creams work over a year in people aged 12 to 50 across the UK and worldwide.
Subjects with acne-prone skin aged 12-50 years with Investigator's Global Assessment (IGA) grades 2-4, evaluating treatment of mild to severe acne vulgaris.Austria - RecruitingPhase III
A study of JNJ-78934804 in participants with moderately to severely active Crohn's disease
This clinical trial is testing a new combination medicine, JNJ-78934804, for moderate to severe Crohn’s disease. It combines two drugs into one injection to target gut inflammation. Researchers want to see if this two-in-one approach works better than a single medicine for people whose previous treatments have stopped working.
Crohn’s diseaseAustria - RecruitingPhase I
Deferred registration - ICON Clinical (UK) Limited/Newcastle Upon Tyne Hospitals NHS Foundation Trust Code: BP45361
This is an early-stage Phase 1 clinical trial taking place in the UK with Newcastle Upon Tyne Hospitals NHS Foundation Trust. Full details about the study are temporarily withheld under official UK research rules. The study plans to include men and women aged between 40 and 75 years.
The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.Austria - AuthorisedHuman Pharmacology (Phase I)- First administration to humans
LAFOV-Lung PET
This early-stage study looks at a new type of lung scan using an advanced scanner called LAFOV PET. Researchers are inviting healthy adult volunteers to take part. The goal is to see how clearly this new technology can view healthy lungs, which could help diagnose lung conditions better in the future.
Investigation in healthy volunteersAustria - AuthorisedTherapeutic confirmatory (Phase III)
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
This study tests an inhaled dry powder medicine called treprostinil palmitil for adults with high blood pressure in the lungs linked to lung scarring. The trial lasts up to two years to see if the medicine is safe and helps improve breathing, walking ability, and overall quality of life.
Pulmonary Hypertension Associated with Interstitial Lung DiseaseAustria - AuthorisedTherapeutic confirmatory (Phase III)
AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
This clinical trial looks at whether cannabidiol (CBD) can help people experiencing psychosis for the first time. Participants take either CBD liquid or a harmless dummy medicine alongside their standard care for six weeks. Researchers want to see if adding CBD helps reduce symptoms and improves overall recovery.
First Episode Psychosis (FEP)Austria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
This clinical trial is studying a medicine called crinecerfont for adults with classic congenital adrenal hyperplasia (CAH). CAH causes the body to make too much male hormone. Researchers want to see if this daily medicine can safely lower these hormone levels over 24 weeks without needing high steroid doses.
Classic Congenital Adrenal Hyperplasia (CAH)Austria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy
This study tests a medicine called Vyvgart in adults with Sjögren's disease who have nerve damage in their hands, legs, or feet. Researchers want to see if regular injections under the skin can ease nerve symptoms, reduce fatigue, and be used safely compared with a dummy treatment.
Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)Austria - AuthorisedTherapeutic exploratory (Phase II)
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
This study looks at the long-term safety of a new medicine called KT-621 for adults with moderate to severe eosinophilic asthma. It is an extension study for people who already took part in an earlier KT-621 trial, checking how well the body tolerates the treatment over 52 weeks.
Uncontrolled Moderate to Severe Eosinophilic AsthmaAustria - AuthorisedTherapeutic confirmatory (Phase III)
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
This study is checking the long-term health of people who took part in an earlier trial for choroidal melanoma, a rare eye cancer. Researchers want to see how well a treatment called bel-sar protects vision and stops the tumour from growing or returning over several years.
Choroidal MelanomaAustria - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
This study tests a new medicine called ontunisertib for people with Crohn's disease who have narrowed sections in their bowel. Researchers want to find out if this daily capsule can reduce tough scar tissue, help widen the bowel, and improve symptoms compared to a dummy pill over one year.
Fibrostenosing Crohn’s DiseaseAustria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
This study tests a new medicine called claseprubart (DNTH103) for generalised myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if the medicine safely improves muscle strength and helps with daily activities compared to a dummy drug (placebo) in adults aged 18 and older.
generalized Myasthenia gravisAustria - AuthorisedPhase II and Phase III (Integrated)
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
This clinical study tests a new tablet called atumelnant for adults with ACTH-dependent Cushing's syndrome. In this condition, the body makes too much cortisol hormone. Researchers want to see if different doses of atumelnant can safely bring cortisol levels back to normal within 12 weeks and improve everyday wellbeing.
• ACTH-Dependent Cushing’s Syndrome.• Pituitary-dependent Cushing´s syndrome.Austria - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
This study is testing a new once-daily dry powder inhaler called treprostinil palmitil for pulmonary arterial hypertension (high blood pressure in the lungs). Doctors want to see if inhaling this medicine once a day helps people walk further and improves their daily symptoms compared with a dummy medicine (placebo).
Pulmonary Arterial HypertensionAustria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisAustria - RecruitingTherapeutic confirmatory (Phase III)
A phase IIIb, open-label, single arm study to evaluate the efficacy and safety of luspatercept in patients with lower-risk MDS and ringsideroblastic phenotype (MDS-RS)
This clinical trial is studying a medicine called luspatercept (Reblozyl) for adults with lower-risk myelodysplastic syndromes (MDS-RS). Researchers want to see if regular injections can help the body produce healthy red blood cells, safely reducing or completely stopping the need for frequent blood transfusions.
Austria - RecruitingTherapeutic confirmatory (Phase III)
A multi-center, open-label, uncontrolled, single-arm, extension study to determine the long-term safety and tolerability of oral lucerastat in adult subjects with Fabry disease.
This study looks at a daily oral medicine called lucerastat for adults with Fabry disease. Researchers want to find out how safe the medicine is and how well people tolerate it over a longer time. Everyone who takes part receives the active medicine, with no dummy pills used.
Fabry diseaseAustria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Global, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ION-682884 in Patients with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
This study is testing a new injection called ION-682884 for adults with a serious heart condition called ATTR-CM. Researchers want to find out if this medicine can protect the heart, lower the need for hospital care, and help people live longer compared to a dummy treatment (placebo).
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)Austria - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis
This study looks at a medicine called nemolizumab for adults with prurigo nodularis. Prurigo nodularis is a skin condition that causes hard, very itchy lumps. Doctors want to see if nemolizumab is safe and effective at calming severe itch and clearing skin nodules over a longer period.
Prurigo NodularisAustria - RecruitingTherapeutic confirmatory (Phase III)
A multicenter, double-blind, randomized study to evaluate the effects of tasimelteon vs. placebo in participants with Delayed Sleep-Wake Phase Disorder (DSWPD)
This study looks at a medicine called tasimelteon for people with Delayed Sleep-Wake Phase Disorder. This condition makes it hard to fall asleep until very late at night. Researchers want to see if taking a daily capsule for 28 days helps people fall asleep earlier than a dummy pill.
Delayed Sleep-Wake Phase Disorder (DSWPD)Austria - RecruitingPhase II and Phase III (Integrated)
A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy
This clinical trial is testing a new injection called efgartigimod for adults with inflammatory muscle disease (myositis). Researchers want to see if the medicine can safely reduce muscle inflammation, improve strength, and help people lower their daily steroid dose compared to a dummy treatment over 52 weeks.
Active Idiopathic Inflammatory Myopathy (IIM)Austria - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)
The WHISTLE-PF study looks at an experimental tablet called ENV-101 (taladegib) for idiopathic pulmonary fibrosis (IPF). Researchers want to see if this treatment helps protect lung function and improves daily symptoms like coughing, breathlessness, and tiredness over 24 weeks compared to a dummy tablet (placebo).
idiopathic pulmonary fibrosisAustria - RecruitingTherapeutic exploratory (Phase II)
A Phase I-II, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients with Resectable Stage I-III Non-Small Cell Lung Cancer, selected according to Biomarker Status
This study is testing whether giving targeted medicine and chemotherapy before surgery helps people with early to mid-stage non-small cell lung cancer. Researchers want to see if matching medicines to a tumour's specific biology can safely shrink the cancer and make surgery more successful.
Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)Austria - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial with Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjögren’s Disease
This study tests whether a medicine called efgartigimod can help adults with primary Sjögren’s disease. Researchers want to see if regular injections under the skin can ease symptoms like joint pain, dry eyes, and dry mouth, and lower overall body inflammation compared with a dummy treatment (placebo).
Primary Sjögren’s DiseaseAustria - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (Anti-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This clinical trial looks at whether giving two cancer medicines after liver cancer surgery or heat treatment helps stop the cancer returning. Researchers are comparing this combination of medicines against standard regular hospital check-ups in adults who have a higher chance of their liver cancer coming back.
High-risk hepatocellular carcinoma (HCC)Austria - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for cancer of the gullet (oesophagus) that cannot be removed by surgery. Researchers want to see if using immunotherapy drugs, called atezolizumab and tiragolumab, after standard chemotherapy and radiotherapy can help stop the cancer from returning and help people live longer.
Unresectable Esophageal Squamous Cell CarcinomaAustria - RecruitingPhase I and Phase II (Integrated)- First administration to humans
A phase 1/1b/2 study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors
This clinical trial is testing a new experimental medicine called AMG 193 for adults with advanced solid tumours. It focuses on cancers that lack a specific gene known as MTAP. Researchers want to find a safe dose and see whether the drug can help shrink or control cancer.
Advanced MTAP-null solid tumorsAustria - RecruitingTherapeutic confirmatory (Phase III)
An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-004)
This study looks at a medicine called sotatercept for adults with pulmonary arterial hypertension (PAH). Researchers want to see how safe it is over a longer period when taken alongside usual treatments. It also checks whether the medicine helps improve walking ability, heart health, and everyday energy levels.
Pulmonary Arterial Hypertension (PAH)Austria - RecruitingTherapeutic exploratory (Phase II)
Primary comparison of Liposomal Anthracycline based treatment versus conventional care strategies prior to allogeneic stem cell transplantation in patients with higher risk MDS or oligoblastic AML
This study looks at a medicine called Vyxeos for adults with serious blood conditions called higher-risk MDS or oligoblastic AML. Doctors want to see if using Vyxeos before a planned stem cell transplant works better and is safer than standard chemotherapy treatments.
Untreated patients with higher risk MDS and oligoblastic AML eligible and intended for allogeneic HCT within the next 6 monthsAustria - RecruitingTherapeutic exploratory (Phase II)
Efficacy and Safety of BT200 (rondaptivon pegol) in Patients with Type 2B von Willebrand disease
This study is testing a new medicine called rondaptivon pegol (BT200) for adults with type 2B von Willebrand disease. Researchers want to see if the medicine can safely raise platelet levels in the blood and reduce how often patients experience bleeding episodes compared to a simple saltwater injection.
Von Willebrand's Disease Type 2BAustria - RecruitingPhase III and phase IV (Integrated)
Effect of Dupilumab an mucus plugs and inflammatory patterns in sEvere asThmAtiC paTients — a Pilot Study (DETACT)
This study tests whether a medicine called dupilumab can clear thick mucus plugs in the airways of adults with severe asthma. By calming lung swelling, doctors hope this injection will help people breathe more easily, reduce chest tightness, and prevent severe asthma attacks.
severe asthmaAustria - RecruitingTherapeutic exploratory (Phase II)
A randomized phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on first line gemcitabine-based chemotherapy
This study looks at two chemotherapy combinations for advanced pancreatic cancer that has spread. It is for people whose cancer worsened after their first treatment with gemcitabine. Researchers want to find out which drug pairing works better at controlling tumour growth and helps people maintain a good quality of life.
metastatic pancreatic cancerAustria - RecruitingTherapeutic exploratory (Phase II)
KontRASt-06: An open-label phase II trial evaluating the activity and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.
This phase 2 clinical trial looks at a new targeted medicine called JDQ443. It is for adults with advanced non-small cell lung cancer that has specific gene changes, including KRAS G12C. The study tests how well this medicine shrinks tumours when used as a first treatment.
Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer with a PD-L1 expression < 1% or a PD-L1 expression ≥ 1% and an STK11 co-mutation.Austria - RecruitingTherapeutic confirmatory (Phase III)
A Pivotal, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects with Hypertension
This clinical trial is testing a new keyhole treatment called the Peregrine System for high blood pressure. The procedure aims to calm overactive nerves near the kidneys. Researchers want to see if this safely lowers blood pressure over several months compared to a dummy procedure.
HypertensionAustria - RecruitingTherapeutic exploratory (Phase II)
RADIANCE Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma; A multicenter, randomized, phase II trial of the German Anal Cancer Study Group
This study tests whether adding an immunotherapy medicine called durvalumab to standard chemotherapy and radiotherapy helps treat stage 2 and 3 anal cancer. Doctors want to see if this combination stops the cancer from returning, lowers the need for stoma surgery, and helps people live longer, healthier lives.
locally-advanced Anal Carcinoma, Anal cancer stage II and IIIAustria - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
This study looks at a new drug called nemolizumab for adults with moderate-to-severe eczema (atopic dermatitis). Researchers want to see how safe the medicine is when used over a long period. They also want to find out how well it clears skin, calms itchiness, and improves sleep.
Atopic DermatitisAustria - AuthorisedPhase II and Phase III (Integrated)
A multicentre, randomized, double-blind, placebo-controlled phase II/III trial investigating the efficacy of anti-FcRn targeting with efgartigimod as a first-line add-on therapy to IVMP in moderate-to-severe attacks of demyelinating diseases of the central nervous system
This clinical trial is testing a new medicine called efgartigimod for adults having a severe flare-up of a nerve condition, such as multiple sclerosis. Researchers want to see if adding this drug to standard steroid drips helps patients recover their eyesight, strength, and mobility faster and more completely.
Demyelinating diseasesAustria - AuthorisedPhase II and Phase III (Integrated)
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
This clinical trial is testing a new targeted medicine called telisotuzumab adizutecan, combined with chemotherapy, for people with advanced pancreatic cancer. Doctors want to see if this new combination shrinks tumours better and helps people live longer compared with standard chemotherapy treatments currently used on the NHS.
Metastatic Pancreatic Ductal AdenocarcinomaPDACAustria - AuthorisedTherapeutic use (Phase IV)
Within-Patient Comparison of Serum Transthyretin Response to Tafamidis Versus Acoramidis: A Pilot Crossover Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
This study compares two heart medicines, tafamidis (Vyndaqel) and acoramidis (BEYONTTRA), in adults with ATTR amyloid cardiomyopathy. Researchers want to see how each drug changes the levels of a specific protective protein in the blood after four weeks. Participants will try both medicines at different times during the study.
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)Austria